Cargando…

Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw

BACKGROUND: Bisphosphonates (BPs) are widely used in clinical practice to prevent and treat bone metabolism-related diseases. Medication-related osteonecrosis of the jaw (MRONJ) is one of the major sequelae of BPs use. Early prediction and intervention of MRONJ are of great significance. METHODS: Ni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mu, Hong, Pang, Ying, Liu, Lili, Liu, Jingbo, Liu, Chunsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061851/ https://www.ncbi.nlm.nih.gov/pubmed/36998031 http://dx.doi.org/10.1186/s40001-023-01095-6

Ejemplares similares

Semaphorin-4D (Sema-4D), the Plexin-B1 ligand, is involved in mouse ovary follicular development
por: Regev, Avital, et al.
Publicado: (2007)

FRI047 Clinical Characteristics Of Patients With Morbid Obesity With Semaphorines (SEMA3D,E,G) And PLXNA3&4 Gene Variants
por: Berra, Maddie, et al.
Publicado: (2023)

Soluble Sema4D Level Is Positively Correlated with Sema4D Expression in PBMCs and Peripheral Blast Number in Acute Leukemia
por: Xue, Li, et al.
Publicado: (2022)

Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication)()
por: Baba, Akira, et al.
Publicado: (2019)

The value of serum Sema4D level in reflecting the inflammatory state of acute ST-segment elevation myocardial infarction
por: Zheng, Koulong, et al.
Publicado: (2023)

The value of serum Sema4D level in predicting the prognosis of patients with acute ST-segment elevation myocardial infarction and with high thrombus burden
por: Bai, Jie, et al.
Publicado: (2023)

Generation and preclinical characterization of an antibody specific for SEMA4D
por: Fisher, Terrence L., et al.
Publicado: (2015)

VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer
por: Chen, Ying, et al.
Publicado: (2018)

Osteonecrosis of the Jaw
por: Lončar Brzak, Božana, et al.
Publicado: (2023)

Medication-related osteonecrosis of the jaw: An update
por: Bansal, Hitesh
Publicado: (2022)

Update on Medication Related Osteonecrosis of the Jaws
por: Boyd, Barry C.
Publicado: (2023)

Promotion of Sema4D expression by tumor-associated macrophages: Significance in gastric carcinoma
por: Li, Han, et al.
Publicado: (2018)

Semaphorin 4D Promotes Skeletal Metastasis in Breast Cancer
por: Yang, Ying-Hua, et al.
Publicado: (2016)

Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
por: He, Lina, et al.
Publicado: (2020)

Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
por: Evans, Elizabeth E, et al.
Publicado: (2015)

Roles of Sema4D and Plexin-B1 in tumor progression
por: Ch'ng, Ewe Seng, et al.
Publicado: (2010)

Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program
por: Regano, Donatella, et al.
Publicado: (2017)

Expression of Semaphorin 3B (SEMA3B) in Various Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association
por: Marcianò, Antonia, et al.
Publicado: (2020)

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?
por: Cassoni, Andrea, et al.
Publicado: (2016)

Severe Maxillary Medication-related Osteonecrosis of the Jaw
por: Kitajima, Shoichiro, et al.
Publicado: (2018)

Medication-related Osteonecrosis of the Jaw: A Review
por: AlDhalaan, Nouf A, et al.
Publicado: (2020)

Anatomical factors in medication-related osteonecrosis of the jaws
por: Correia, J. A., et al.
Publicado: (2021)

Medication-related osteonecrosis of the jaw: Prosthodontic considerations
por: Ali, Islam E., et al.
Publicado: (2022)

Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw
por: Roato, Ilaria, et al.
Publicado: (2023)

Serum Soluble Semaphorin 4D is Associated with Left Atrial Diameter in Patients with Atrial Fibrillation
por: Xiang, Li, et al.
Publicado: (2015)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis
por: Lontos, Konstantinos, et al.
Publicado: (2018)

Increased Levels of Plasma Soluble Sema4D in Patients with Heart Failure
por: Lu, Qiongyu, et al.
Publicado: (2013)

Inhibition of RANKL and Sema4D improves residual ridge resorption in mice
por: Hisamoto, Meri, et al.
Publicado: (2022)

Impact of leptin or melatonin on Sema4D overexpression-related bone metabolism
por: Lin, Zhenen, et al.
Publicado: (2023)

The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer
por: Jiang, Hongchao, et al.
Publicado: (2016)

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
por: Karayan-Tapon, L, et al.
Publicado: (2008)

Sema6B, Sema6C, and Sema6D Expression and Function during Mammalian Retinal Development
por: Matsuoka, Ryota L., et al.
Publicado: (2013)

The extracellular SEMA domain attenuates intracellular apoptotic signaling of semaphorin 6A in lung cancer cells
por: Shen, Cheng-Ying, et al.
Publicado: (2018)

Increased Prevalence of Bisphosphonate-Related Osteonecrosis of the Jaw with Vitamin D Deficiency in Rats
por: Hokugo, Akishige, et al.
Publicado: (2010)

Uncommon presentation of potential medication-related osteonecrosis of the jaw
por: Kim, Seong-Gon, et al.
Publicado: (2016)

Medication-related osteonecrosis of the jaw: Clinical and practical guidelines
por: Rosella, Daniele, et al.
Publicado: (2016)

Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw
por: Kim, Jin-Woo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bk43mquitiu11b2nfpahqccaav